A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam
Objectives: Relebactam is a small molecule β-lactamase inhibitor under clinical investigation for use as a fixed-dose combination with imipenem/cilastatin. Here we present a translational pharmacokinetic/pharmacodynamic mathematical model to support optimal dose selection of relebactam. Methods: Dat...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-12-01
|
Series: | International Journal of Infectious Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971219303522 |
id |
doaj-c36773d0ea484fcda6c8a1876dc58de4 |
---|---|
record_format |
Article |
spelling |
doaj-c36773d0ea484fcda6c8a1876dc58de42020-11-25T01:32:27ZengElsevierInternational Journal of Infectious Diseases1201-97122019-12-01895561A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactamPratik Bhagunde0Zufei Zhang1Fred Racine2Donna Carr3Jin Wu4Katherine Young5Matthew L. Rizk6Sanofi US, 55 Corporate Drive, Bridgewater, NJ, 08807, USAMerck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USAMerck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USAMerck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USAMerck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USAMerck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USAMerck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA; Corresponding author.Objectives: Relebactam is a small molecule β-lactamase inhibitor under clinical investigation for use as a fixed-dose combination with imipenem/cilastatin. Here we present a translational pharmacokinetic/pharmacodynamic mathematical model to support optimal dose selection of relebactam. Methods: Data derived from in vitro checkerboard and hollow fiber infection studies of imipenem-resistant strains of Pseudomonas aeruginosa were incorporated into the model. The model integrates the effect of relebactam concentration on imipenem susceptibility in a semi-mechanistic manner using the checkerboard data and characterizes the bacterial time-kill profiles from the hollow fiber infection model data. Results: Simulations demonstrated that the ratio of the area under the concentration-time curve for free drug to the minimum inhibitory concentration (fAUC/MIC) was the pharmacokinetic driver for relebactam, with a target fAUC/MIC = 7.5 associated with 2-log kill. At a clinical dose of 250 mg relebactam, greater than 2-log reductions in bacterial load are projected for imipenem-resistant strains with an imipenem/relebactam MIC ≤ 4 μg/mL. Conclusions: The study confirms that the pharmacokinetic/pharmacodynamic driver for relebactam is fAUC/MIC, that an fAUC/MIC ratio of 7.5 is associated with 2-log kill in vitro, and that a 250 mg clinical dose of relebactam achieves this target value when delivered in combination with imipenem/cilastatin. Keywords: Imipenem, Relebactam, Translational, PK/PD, Dose selectionhttp://www.sciencedirect.com/science/article/pii/S1201971219303522 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pratik Bhagunde Zufei Zhang Fred Racine Donna Carr Jin Wu Katherine Young Matthew L. Rizk |
spellingShingle |
Pratik Bhagunde Zufei Zhang Fred Racine Donna Carr Jin Wu Katherine Young Matthew L. Rizk A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam International Journal of Infectious Diseases |
author_facet |
Pratik Bhagunde Zufei Zhang Fred Racine Donna Carr Jin Wu Katherine Young Matthew L. Rizk |
author_sort |
Pratik Bhagunde |
title |
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam |
title_short |
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam |
title_full |
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam |
title_fullStr |
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam |
title_full_unstemmed |
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam |
title_sort |
translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam |
publisher |
Elsevier |
series |
International Journal of Infectious Diseases |
issn |
1201-9712 |
publishDate |
2019-12-01 |
description |
Objectives: Relebactam is a small molecule β-lactamase inhibitor under clinical investigation for use as a fixed-dose combination with imipenem/cilastatin. Here we present a translational pharmacokinetic/pharmacodynamic mathematical model to support optimal dose selection of relebactam. Methods: Data derived from in vitro checkerboard and hollow fiber infection studies of imipenem-resistant strains of Pseudomonas aeruginosa were incorporated into the model. The model integrates the effect of relebactam concentration on imipenem susceptibility in a semi-mechanistic manner using the checkerboard data and characterizes the bacterial time-kill profiles from the hollow fiber infection model data. Results: Simulations demonstrated that the ratio of the area under the concentration-time curve for free drug to the minimum inhibitory concentration (fAUC/MIC) was the pharmacokinetic driver for relebactam, with a target fAUC/MIC = 7.5 associated with 2-log kill. At a clinical dose of 250 mg relebactam, greater than 2-log reductions in bacterial load are projected for imipenem-resistant strains with an imipenem/relebactam MIC ≤ 4 μg/mL. Conclusions: The study confirms that the pharmacokinetic/pharmacodynamic driver for relebactam is fAUC/MIC, that an fAUC/MIC ratio of 7.5 is associated with 2-log kill in vitro, and that a 250 mg clinical dose of relebactam achieves this target value when delivered in combination with imipenem/cilastatin. Keywords: Imipenem, Relebactam, Translational, PK/PD, Dose selection |
url |
http://www.sciencedirect.com/science/article/pii/S1201971219303522 |
work_keys_str_mv |
AT pratikbhagunde atranslationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT zufeizhang atranslationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT fredracine atranslationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT donnacarr atranslationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT jinwu atranslationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT katherineyoung atranslationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT matthewlrizk atranslationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT pratikbhagunde translationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT zufeizhang translationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT fredracine translationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT donnacarr translationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT jinwu translationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT katherineyoung translationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam AT matthewlrizk translationalpharmacokineticpharmacodynamicmodeltocharacterizebacterialkillinthepresenceofimipenemrelebactam |
_version_ |
1725082093644414976 |